"The Stefanie Spielman Comprehensive Breast Center offers a full continuum of breast cancer care — from prevention and screening through detection, diagnosis, treatment and survivorship — all in one world-class facility. At the Center, our internationally renowned breast cancer experts focus on preventing, detecting, treating and yes, curing, breast cancer by working together across numerous medical disciplines (medical, surgical and radiation oncologists; radiologists; pharmacists; reconstructive surgeons; pathologists and more) to design the very best treatment plan and therapies to target each patient’s specific breast cancer."

During the past decade, Stefanie Spielman Comprehensive Breast Cancer conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Stefanie Spielman Comprehensive Breast Cancer" #1 sponsor was "Pfizer" with 4 trials, followed by "Celcuity, Inc." with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored, "Rutgers, The State University of New Jersey" with 1 trials sponsored and "Washington University School of Medicine" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Stefanie Spielman Comprehensive Breast Cancer" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Incyte Corporation" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "National Cancer Institute (NCI)" with 1 trials as a collaborator and "Oncolytics Biotech" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Stefanie Spielman Comprehensive Breast Cancer" are "Breast Cancer" (2 trials), "Anatomic Stage IV Breast Cancer AJCC v8" (1 trials), "Breast Carcinoma" (1 trials), "Early Breast Cancer" (1 trials) and "Locally Advanced Breast Carcinoma" (1 trials). Many other conditions were trialed in "Stefanie Spielman Comprehensive Breast Cancer" in a lesser frequency.

Most popular intervention types in "Stefanie Spielman Comprehensive Breast Cancer" are "Drug" (6 trials), "Biological" (2 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "5-FU" (1 trials), "Bevacizumab" (1 trials), "Capecitabine" (1 trials), "Cetuximab" (1 trials) and "Encorafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Stefanie Spielman Comprehensive Breast Cancer" are 4 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "Stefanie Spielman Comprehensive Breast Cancer". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Stefanie Spielman Comprehensive Breast Cancer, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Stefanie Spielman Comprehensive Breast Cancer, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".